Small-molecule inhibitors of ERK-mediated immediate early gene expression and proliferation of melanoma cells expressing mutated BRaf.
Ramin Samadani, Jun Zhang, Amanda Brophy, Taiji Oashi, U Deva Priyakumar, E Prabhu Raman, Franz J St John, Kwan-Young Jung, Steven Fletcher, Edwin Pozharski, Alexander D MacKerell, Paul Shapiro
文献索引:Biochem. J. 467(3) , 425-38, (2015)
全文:HTML全文
摘要
Constitutive activation of the extracellular-signal-regulated kinases 1 and 2 (ERK1/2) are central to regulating the proliferation and survival of many cancer cells. The current inhibitors of ERK1/2 target ATP binding or the catalytic site and are therefore limited in their utility for elucidating the complex biological roles of ERK1/2 through its phosphorylation and regulation of over 100 substrate proteins. To overcome this limitation, a combination of computational and experimental methods was used to identify low-molecular-mass inhibitors that are intended to target ERK1/2 substrate-docking domains and selectively interfere with ERK1/2 regulation of substrate proteins. In the present study, we report the identification and characterization of compounds with a thienyl benzenesulfonate scaffold that were designed to inhibit ERK1/2 substrates containing an F-site or DEF (docking site for ERK, FXF) motif. Experimental evidence shows the compounds inhibit the expression of F-site containing immediate early genes (IEGs) of the Fos family, including c-Fos and Fra1, and transcriptional regulation of the activator protein-1 (AP-1) complex. Moreover, this class of compounds selectively induces apoptosis in melanoma cells containing mutated BRaf and constitutively active ERK1/2 signalling, including melanoma cells that are inherently resistant to clinically relevant kinase inhibitors. These findings represent the identification and initial characterization of a novel class of compounds that inhibit ERK1/2 signalling functions and their potential utility for elucidating ERK1/2 and other signalling events that control the growth and survival of cancer cells containing elevated ERK1/2 activity.
相关化合物
相关文献:
2014-08-01
[Mol. Plant 7(8) , 1365-83, (2014)]
2014-06-02
[J. Exp. Med. 211(6) , 1079-91, (2014)]
2012-07-01
[Int. J. Obes. 38(12) , 1538-44, (2014)]
2014-01-01
[PLoS Biol. 12(1) , e1001758, (2014)]
2014-12-11
[Oncogene 33(50) , 5688-96, (2014)]